Semi-Annual Consolidated Statement Of Income

K Pharma,Inc. - Filing #7269885

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Semi-annual consolidated statement of income
Statement of income
Net sales	—	—	—	JPY	—	1,000,000,000 JPY	—	—
Cost of sales	—	—	—	JPY	—	90,000,000 JPY	—	—
Ordinary profit (loss)	—	—	—	-836,243,000 JPY	—	344,184,000 JPY	—	—
Gross profit (loss)	—	—	—	JPY	—	910,000,000 JPY	—	—
Selling, general and administrative expenses
Remuneration for directors (and other officers)	—	—	—	121,800,000 JPY	—	69,200,000 JPY	—	—
Taxes and dues	—	—	—	5,330,000 JPY	—	29,071,000 JPY	—	—
Selling, general and administrative expenses	—	—	—	836,346,000 JPY	—	543,942,000 JPY	—	—
Extraordinary losses	—	—	—	7,861,000 JPY	—	43,107,000 JPY	—	—
Profit (loss) before income taxes	—	—	—	-844,104,000 JPY	—	301,076,000 JPY	—	—
Operating profit (loss)	—	—	—	-836,346,000 JPY	—	366,057,000 JPY	—	—
Income taxes - current	—	—	—	2,350,000 JPY	—	40,746,000 JPY	—	—
Non-operating income
Interest income	—	—	—	265,000 JPY	—	16,000 JPY	—	—
Non-operating income	—	—	—	1,261,000 JPY	—	66,000 JPY	—	—
Non-operating expenses
Non-operating expenses	—	—	—	1,158,000 JPY	—	21,939,000 JPY	—	—
Income taxes	—	—	—	2,350,000 JPY	—	40,746,000 JPY	—	—
Profit (loss)	-846,455,000 JPY	-846,455,000 JPY	-846,455,000 JPY	-846,455,000 JPY	260,330,000 JPY	260,330,000 JPY	260,330,000 JPY	260,330,000 JPY
Extraordinary losses
Impairment losses	—	—	—	7,861,000 JPY	—	43,107,000 JPY	—	—